Logo Image
|Articles|October 15, 2009

Dutasteride maker files NDA for prostate cancer risk reduction

p>GlaxoSmithKline has filed a supplemental new drug application with the FDA for dutasteride (Avodart) for prostate cancer risk reduction among men at increased risk of developing the disease.

GlaxoSmithKline has filed a supplemental new drug application with the FDA for dutasteride (Avodart) for prostate cancer risk reduction among men at increased risk of developing the disease.

European Union filings also are under way via the European Mutual Recognition Variation Procedure, with Sweden acting as the Reference Member State.

Dutasteride is not currently approved or licensed to treat or reduce the risk of prostate cancer.

Related Content

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified
Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Radioligand Therapy 101: The Science Behind the Strategy
Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more
Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease
Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more